Detection of gene fusion transcripts in Acute Lymphoblastic Leukemia (ALL) from ribonucleic acid (RNA). RNA is isolated from bone marrow aspirates or peripheral blood and the cDNA sequence of targeted regions of the ABL1, ABL2, BCR, CRLF2, CSF1R, ETV6, IL2RB, IL3, JAK2, KMT2A, MEF2D, MLLT10, NUP98, PAX5, PDGFRB, PTK2B, RUNX1 ,TAL1, TCF3, TLX1, TLX3, TYK2, and ZNF384 genes is determined using next-generation sequencing (NGS) technology.

When serial or subsequent COMPASS® evaluations are requested on the same patient and deemed clinically appropriate by a Genoptix Hematopathologist, Genoptix will automatically provide a CHART® report, unless otherwise indicated by the ordering physician. CHART® includes all medically necessary technologies, and a consultative review and correlation with relevant prior findings and intervening treatment by a Genoptix Hematopathologist.

The client’s pathologist must provide the cytogenetics report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, blood or bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), and molecular tests as medically necessary.

The client’s pathologist must provide the flow cytometry report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.

The client’s pathologist must provide the morphology report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.

Includes COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.

Includes COMPASS® consultation report, clinical pathology evaluation, blood morphology (up to 10 cytochemical stains), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.